Takeda Completes Acquisition of ARIAD Pharmaceuticals Inc

Industry Reports
Typography

Takeda Pharmaceutical Company Limited announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc for $24.00 per share in cash.

“We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals. The addition of ARIAD’s innovative targeted therapies and research and development capabilities strengthens and diversifies ouroncology business, positioning Takeda for sustainable long-term growth in this priority therapeutic area,” said Christophe Weber, president and chief executive officer of Takeda.

“We are particularly excited by the global potential of brigatinib, an investigational drug product, which we believe will become a best-in-class ALK inhibitor for non-small cell lung cancer with the potential to achieve peak annual sales of over $1 billion. We are also impressed with the swiftness and agility of Takeda and ARIAD employees as they have planned for a successful integration while remaining focused on strategic goals. This bodes very well for the future of our combined business, and we look forward to building on this strong start to maximize the benefit of Iclusig® (ponatinib) and potential of brigatinib for cancer patients.”

"The acquisition of ARIAD is transformational for Takeda Oncology. Iclusig enhances our strong position in hematology in the U.S., and brigatinib has the potential to broaden our solid tumor franchise globally,” said Christophe Bianchi, president of Takeda Oncology. “There is a strong cultural fit between our two companies, with a shared mission to advance innovative therapies to improve the lives of patients with cancer. We have been working together over the past month to plan for a smooth integration of our businesses and we will work closely with regulatory authorities on our brigatinib market authorization submissions.”

Takeda continues to expect the transaction to be accretive to Underlying Core Earnings by FY2018. Strong revenue growth and synergy savings will offset increased sales and marketing costs for the anticipated brigatinib launch.

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. Additional information about Takeda is available through its corporate website, www.Takeda.com.

Media and Investor Contacts

Noriko Higuchi
This email address is being protected from spambots. You need JavaScript enabled to view it.
+81 (0) 3-3278-2306

Takeda Media outside Japan

Shawn Goodman
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-415-250-0766

Japanese Media
Tsuyoshi Tada
This email address is being protected from spambots. You need JavaScript enabled to view it.
+81 (0) 3-3278-2417

Kal Goldberg, Finsbury
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-646-805-2005

Chris Ryall, Finsbury
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-646-805-2078